Bret Hughes, MD
Ophthalmology · Detroit, MINPI 1760420822
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,325 of the $122,973 with a category attached, or 75.1%. Bausch & Lomb, A Division Of Bausch Health US, LLC accounts for 72.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $67,465 and has fallen 69.5% since, to $20,607 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $551.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$89K
- Bausch & Lomb Americas Inc.$32K
- AbbVie$917
- NEW World Medical,inc.$535
- Alcon$289
- Ivantis, Inc$289
- plus $556 from 11 others
Across 4 payments — averaging $2675.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$11K
What the payments were for
- Consulting fees$9,5338%
- Speaking & faculty fees$92,32575%
- Travel & lodging$14,80312%
- Food & beverage$6,2945%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 102 | $88,668 |
| Bausch & Lomb Americas Inc. | 37 | $31,720 |
| AbbVie(2 entities) | 35 | $917 |
| NEW World Medical,inc. | 17 | $535 |
| Alcon | 12 | $289 |
| Ivantis, Inc | 2 | $289 |
| Glaukos Corporation | 2 | $207 |
| Regeneron Healthcare Solutions, Inc. | 3 | $92 |
| Genentech USA, Inc. | 3 | $74 |
| Sight Sciences, Inc. | 3 | $70 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Davol Inc. | 1 | $18 |
| Thea Pharma Inc. | 1 | $18 |
| Omeros Corporation | 1 | $18 |
| Dompe US, Inc. | 1 | $18 |
| Novartis | 1 | $11 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$117,878
- MIEBO$322
- XIIDRA$322
- Hydrus$289
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- XEN GLAUCOMA TREATMENT SYSTEM$122
- iStent inject Trabecular Micro-Bypass Stent System$117
- DURYSTA$116
- LOTEMAX SM$111
- PROLENSA$111
- Hydrus Microstent$106
How this compares
$122,973 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 276 | $144,263 |
| RocklatanNetarsudil Mesylat/Latanoprost | 248 | $130,381 |
| LumiganBimatoprost | 256 | $117,677 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 220 | $74,424 |
| CombiganBrimonidine Tartrate/Timolol | 146 | $68,650 |
| RestasisCyclosporine | 50 | $43,505 |
| RhopressaNetarsudil Mesylate | 70 | $43,139 |
| Brimonidine Tartrate | 832 | $39,082 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 147 | $38,952 |
| Latanoprost | 1,438 | $26,603 |
| Alphagan PBrimonidine Tartrate | 31 | $24,938 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 672 | $18,660 |
| Travoprost | 68 | $16,685 |
| Timolol Maleate | 450 | $15,564 |
| Prednisolone Acetate | 308 | $15,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P, Restasis Multidose | $917 | $265,026497 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $31,720 | $144,263276 claims |
| AlconSimbrinza, Azopt | $289 | $86,121246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Detroit
- Pradeepa YoganathanDetroit$115K
- Michael ColemanDetroit$20K
- Daniel ZuckerbrodDetroit$16K
- Daniel AppleDetroit$10K
- Gabriel SosneDetroit$9K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.